ICU Medical Inc. (NASDAQ:ICUI) VP Steven Riggs sold 44,739 shares of the company’s stock in a transaction on Tuesday, September 13th. The stock was sold at an average price of $121.78, for a total transaction of $5,448,315.42. Following the completion of the transaction, the vice president now owns 675 shares of the company’s stock, valued at $82,201.50. The sale was disclosed in a filing with the SEC, which is available at this link.
Steven Riggs also recently made the following trade(s):
- On Wednesday, June 29th, Steven Riggs sold 20,000 shares of ICU Medical stock. The stock was sold at an average price of $110.00, for a total transaction of $2,200,000.00.
Shares of ICU Medical Inc. (NASDAQ:ICUI) opened at 122.30 on Monday. The stock has a market capitalization of $1.97 billion, a P/E ratio of 36.42 and a beta of 0.49. ICU Medical Inc. has a 12 month low of $85.56 and a 12 month high of $128.93. The company’s 50-day moving average is $122.38 and its 200 day moving average is $108.42.
ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Monday, August 8th. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. The company earned $96.70 million during the quarter, compared to analyst estimates of $89.66 million. ICU Medical had a net margin of 14.94% and a return on equity of 10.33%. ICU Medical’s quarterly revenue was up 15.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.97 earnings per share. Equities research analysts predict that ICU Medical Inc. will post $4.54 earnings per share for the current year.
Several research analysts recently issued reports on the stock. Piper Jaffray Cos. reiterated a “neutral” rating and issued a $119.00 price target (up from $115.00) on shares of ICU Medical in a research note on Thursday, August 11th. Zacks Investment Research upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $140.00 price target for the company in a research note on Friday, August 12th.
A number of hedge funds and other institutional investors have recently bought and sold shares of ICUI. Tower Research Capital LLC TRC purchased a new position in ICU Medical during the second quarter valued at approximately $124,000. Bank of Montreal Can purchased a new position in ICU Medical during the second quarter valued at approximately $133,000. PineBridge Investments L.P. raised its position in ICU Medical by 3.6% in the second quarter. PineBridge Investments L.P. now owns 1,835 shares of the company’s stock valued at $207,000 after buying an additional 63 shares during the last quarter. Amalgamated Bank purchased a new position in ICU Medical during the second quarter valued at approximately $214,000. Finally, M&T Bank Corp raised its position in ICU Medical by 3.3% in the first quarter. M&T Bank Corp now owns 2,117 shares of the company’s stock valued at $220,000 after buying an additional 67 shares during the last quarter. 89.50% of the stock is owned by institutional investors.
About ICU Medical
ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.